BS_M85CXHDV
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 27.726675427069644
- age_years
- 18.016
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.629
- INTERFERON_ALPHA_RESPONSE+0.618
- ALLOGRAFT_REJECTION+0.587
- INTERFERON_GAMMA_RESPONSE+0.584
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.573
- INFLAMMATORY_RESPONSE+0.538
- ANGIOGENESIS+0.502
- COAGULATION+0.502
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.488
- COMPLEMENT+0.484
Top 10 suppressed
- SPERMATOGENESIS-0.073
- KRAS_SIGNALING_DN-0.052
- HEDGEHOG_SIGNALING-0.026
- UV_RESPONSE_DN+0.004
- OXIDATIVE_PHOSPHORYLATION+0.013
- PANCREAS_BETA_CELLS+0.029
- WNT_BETA_CATENIN_SIGNALING+0.058
- DNA_REPAIR+0.079
- PROTEIN_SECRETION+0.081
- ANDROGEN_RESPONSE+0.095
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.944 |
| 2 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.941 |
| 3 | MNG256 | — | — | 0.940 |
| 4 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.926 |
| 5 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.924 |
| 6 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.923 |
| 7 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.921 |
| 8 | SRR934903 | — | — | 0.921 |
| 9 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.920 |
| 10 | BS_1JDG6JV5 | pilocytic astrocytoma | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 47 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.629 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.618 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.587 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.584 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.573 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.538 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.502 | Remibrutinib | — uncovered |
| COAGULATION | 0.502 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.488 | Inavolisib | — uncovered |
| COMPLEMENT | 0.484 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.464 | Inavolisib | — uncovered |
| APOPTOSIS | 0.429 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.416 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.389 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.371 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.348 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.343 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.332 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |